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Abstract
Purpose To compare characteristics of patients, the risk of
recurrence, and mortality among adult patients with primary
resectable gastrointestinal stromal tumor (GIST) receiving
short-term (6–12 months) versus long-term (≥24 months)
imatinib therapy.
Methods Detailed information on primary resectable KIT-
positive GIST patients initiated on imatinib adjuvant therapy
was retrospectively collected for short- and long-term ima-
tinib patients from 318 US oncologists using an online data
collection form. Patient characteristics were compared using
Wilcoxon and Chi-square tests. Disease recurrence and
mortality rates were compared using multivariate Cox pro-
portional hazard models.
Results Among the 406 short-term and 406 long-term ima-
tinib patients, the median follow-up was 916 and 970 days,
respectively. While patients generally had similar demo-
graphic characteristics, the short-term group had a higher
prevalence of cardiovascular and ischemic heart diseases
and patients in the long-term group had a higher pre-
surgery risk profile. This finding was consistent with the
main reason reported by oncologists for prescribing adju-
vant imatinib over longer duration, i.e., patient risk profile.
Disease recurrence [5.9 versus 1.2 %, (p<.001)] and mor-
tality rates [7.1 % versus 2.0 %, (p<.001)] were higher in
short- versus long-term patients. The adjusted risk of recur-
rence was 5.30 times (p<.001) higher, and mortality risk
was 4.02 times (p<.001) higher in short- versus long-term
patients.
Conclusions Patient risk profile is an important factor in
oncologists’ decisions to prescribe adjuvant imatinib. De-
spite the higher risk profile observed in long-term patients,
the long-term use of imatinib was associated with a reduc-
tion in long-term risk of disease recurrence and mortality.
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Background
A gastrointestinal stromal tumor (GIST) is a type of soft-
tissue sarcoma that usually develops in cells within the wall
of the stomach or intestines. GISTs may result from the
over-expression or activation of mutation in KIT (CD117)
protein or platelet-derived growth factor receptor alpha
which provides a stimulus for tumor cell proliferation [1,
2]. The incidence of a GIST is estimated to be approximate-
ly 3,000–6,000 cases per year in the US [3, 4]. Most com-
mon GISTs sites are stomach (60 %), jejunum and ileum
(30 %), duodenum (5 %), and colorectum (<5 %) [5, 6].
Approximately 20 % to 25 % of gastric GISTs and 40 % to
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50 % of small intestinal GISTs are found to be malignant
[6].
The standard of care in GIST management varies depend-
ing on the stage of the tumor, the presence of metastases, and
the patient’s risk profile. Tumor resection with clear margins
remains the mainstay of treatment for localized primary re-
sectable GISTs. However, a large proportion of patients may
develop recurrent/metastatic disease even after curative sur-
gery [7]. A recent study reported that more than 50 % of
patients undergoing surgery relapse within 5 years [8, 9].
The introduction of tyrosine kinase inhibitors with imatinib
(Gleevec® Novartis Pharmaceuticals) has changed the treat-
ment landscape by increasing disease-free survival in GIST
patients. Currently, imatinib is approved as adjuvant therapy
following surgery and in adults with KIT-positive unresect-
able and/or metastatic malignant GIST [10]. Although initial
approval was based on improvements in recurrence-free sur-
vival (RFS) following 1 year of imatinib treatment compared
with a placebo, a recent multicenter, prospective, randomized
Phase III study comparing 3 years versus 1 year of adjuvant
imatinib showed superior clinical outcomes among patients
receiving imatinib for 3 years [11]. RFS for patients receiving
3 years of adjuvant imatinib at years 3 and 5 were 88.1 % and
67.4 % versus 62.1 % and 50.3 % for patients receiving 1 year
of adjuvant imatinib (hazard ratio [HR] 0.46, 95 % CI, 0.31–
0.65, p<0.0001). Similarly, overall survival at years 3 and 5
was higher for patients on 3 years imatinib adjuvant compared
with patients on 1 year adjuvant (96.3 % and 92.0 % versus
94.0 % and 81.7 %) (HR of 0.45, 95 % CI, 0.22–0.89, p0
0.019) [11]. Based on these findings, the National Compre-
hensive Cancer Network (NCCN) panel of experts recom-
mended in the 2012 NCCN Guideline to consider adjuvant
imatinib for at least 36 months in high-risk patients [12].
To date, there are no specific guidelines on the optimal
duration of adjuvant imatinib following GIST resection. Al-
though long-term imatinib use has been shown to be beneficial
in clinical trials, there is limited information on the imatinib
treatment duration, risk of disease recurrence, and clinical
outcomes in GIST patients undergoing treatment with adjuvant
imatinib in a non-trial setting. The objective of this study was
to compare characteristics of GIST patients and the risk of
recurrence and survival among primary resectable GIST
patients receiving short-term (6–12 months) versus long-term
(≥24 months) imatinib adjuvant therapy in clinical practice.
Methods
Data Source and Sample Selection
Data were collected from patient charts via a physician-
administered online data collection form. A survey/chart
extraction form was developed specifically for this study.
Oncologists and sarcoma specialists were recruited from a
panel of over 200,000 medical professionals in the United
States from a vendor specializing in online physician sur-
veys. Physicians were invited by E-mail to participate in the
study and to provide clinical information for a maximum of
five patients who met the study selection criteria. Patients
were randomly selected by physicians from a list of their
eligible patients. Physicians were requested to consider only
patients for whom they had complete clinical GIST-related
information for at least 2 years following imatinib initiation.
If a patient died within 2 years following imatinib initiation,
all clinical information up until the time of death was col-
lected. Patients were considered to be eligible for this study
if they met the following criteria: (1) age of 18 years or
older; (2) diagnosis of primary resectable KIT-positive GIST
(CD117) and underwent surgery as primary treatment on or
after 12/19/20081; (3) no evidence of metastases prior to
surgery and no evidence of residual macroscopic disease
after surgery; (4) initiation of imatinib adjuvant therapy
within 12 weeks following surgery date followed by con-
tinuous imatinib use for at least 6 months (no treatment gap
>60 consecutive days); and (5) no use of other c-KIT
inhibitors (imatinib or sunitinib), biologics, chemotherapy,
or radiation therapy prior to imatinib initiation.
Based on imatinib treatment duration, patients were clas-
sified into two mutually exclusive cohorts: (1) short-term
imatinib use (short-term group): treated with imatinib con-
tinuously for at least 6 months but no more than 12 months;
and (2) long-term imatinib use (long-term group): treated
with imatinib continuously for at least 24 months. In order
to measure the impact of the short-term use versus long-term
use of imatinib, patients in the short-term group who had a
recurrence within the first 12 months—if they were still on
imatinib—were excluded as the recurrence could not be
attributed to the treatment interruption. Similarly, patients
in the long-term group who had a disease recurrence within
the first 12 months were excluded as these patients experi-
enced a recurrence before they could benefit from the long-
term imatinib use.
Data Collection
A data collection form was designed to collect patient/clin-
ical information via a physician survey/chart extraction.
First, physicians were asked to record information on their
practice, general opinions regarding GIST treatment includ-
ing role of risk profile in treatment decisions, and imatinib
treatment initiation, duration, and discontinuation. Next,
physicians were requested to record detailed clinical infor-
mation, including demographics, comorbidity profile, sur-
gery details, GIST-related characteristics, imatinib treatment
1 FDA approval date in adjuvant setting
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characteristics, disease recurrence, and mortality for patients
selected for this study.
Outcome Measures
Patient and Physician Characteristics
Patients’ characteristics were observed prior to/on the
surgery date. Patient’ demographics (age, gender),
comorbidity profile, GIST-related characteristics (mitotic
count, tumor size, location, rupture during surgery, mu-
tation analyses), and imatinib treatment characteristics
(average dose prescribed, treatment duration, reason for
the choice of treatment) were collected. The pre-
treatment Fletcher risk score categories and the Miettinen
risk score, indicating the risk of progression, were also
computed respectively for patients with complete mitotic
information and for patients with gastric and small intes-
tinal GISTs [5, 13, 14].
Data on physicians’ characteristics (practice setting, prac-
tice size and specialty, region), perceptions, and prescribing
patterns were also collected.
Clinical Outcomes: Disease Recurrence and Mortality
The risk of recurrence was compared between patients re-
ceiving short-term versus long-term adjuvant imatinib. Dis-
ease recurrence was defined as the reappearance of GIST at
the same location or as a new GIST lesion and measured
during the period spanning from surgery date until the first
disease recurrence, death of the patient, or the last date on
which the physician had complete patient information,
whichever occurred first.
Mortality rates were compared among patients receiving
short-term versus long-term imatinib adjuvant therapy and
measured during the period spanning from the surgery date
until the date of death, or the last date on which the physi-
cian had complete patient information, whichever occurred
first.
Statistical Analyses
Patient and Physician Characteristics
Patient characteristics and physician practice related differ-
ences were compared between patients in the short-term and
long-term group using Wilcoxon rank–sum tests for contin-
uous variables and Chi-square tests for categorical variables.
Clinical Outcomes: Disease Recurrence and Mortality Rates
The proportion of patients who had at least one disease
recurrence and who died over the study period was reported.
In addition, to account for varying observation period dura-
tions, separate multivariate Cox proportional-hazards mod-
els were used to compare mortality and disease recurrence
risks between patients in the long-term and short-term
groups while controlling for differences in age, gender,
GIST size, GIST location, and mitotic count. Results were
reported as hazards ratios with their 95 % confidence inter-
vals and pvalues.
All statistical analyses were carried out with SAS 9.3
statistical software (SAS Institute, Inc., Cary, NC, USA).
Results
Over the 2-month collection period, a total of 318 specialists
provided information from patient charts. Over a total of
7,221 eligible patients (short-term, 4,045 versus long-term,
3,176) information was collected from 812 eligible patients
receiving adjuvant imatinib (short-term, 406 versus long-
term, 406) (Fig. 1). The median duration of the observation
period was 970 and 916 for long-term and short-term
patients, respectively.
Patient and Physician Characteristics
Demographics and Comorbidity Profile
Most patients were Caucasians (short-term, 71 %, long-
term, 75 %, p00.236), from the north east (short-term,
31 %, long-term, 35 %, p00.203) and south regions of the
US (short-term, 34 %, long-term, 29 %, p00.199). While
patients were similar in age (approximately 59 years old, p0
0.113), the short-term group included fewer males (59 %
versus 70 %, p00.002) (Table 1). The comorbidity profile
was generally well balanced between the two groups. The
ten most prevalent comorbidities were presented. However,
the short-term group had a statistically significant higher
prevalence of cardiovascular (11 % versus 6 %, p00.004)
and ischemic heart disease (4 % versus 2 %, p00.020)
(Table 1).
GIST-Related Characteristics
The average tumor size before resection was significantly
lower in the short-term group (6.9 cm versus 8.1 cm, p<
0.001), and the short-term group had a significantly higher
proportion of patients with a low mitotic count (17.5 %
versus 9.6 % p00.001) (Table 2). Differences were also
observed in GIST locations; more patients in the long-term
group had a GIST located in the stomach (54 % versus
46 %, p00.035), and fewer had a GIST located in the pelvis
(0.7 % versus 3.7 %, p00.004) (Table 2). Patients in the
long-term group had a higher Miettinen risk score (0.40
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versus 0.32, p00.004). Similarly, a higher proportion of
patients in the long-term group had a high risk Fletcher
score (49 % versus 40 %, p00.013).
For approximately half of the patients, no mutation test
analyses were performed (Table 2). The main reasons stated
by physicians for not performing KIT mutation tests were that
Adult patients with ≥1 diagnosis of primary resectable GIST positive for KIT (CD117)  
who underwent a surgery as primary treatment on or after 12/19/2008
Had no evidence of metastases 
on/around surgery date and no 
evidence of residual macroscopic 
disease after surgery
Initiated on imatinib as adjuvant therapy within 12 weeks following surgery date and used imatinib 
continuously for ≥ 6 months 
Did not use c-KIT inhibitors (imatinib or sunitinib), other 
biologic, chemotherapy, or radiation therapy prior 
to imatinib treatment initiation
Had no evidence of disease recurrence, while on imatinib 
treatment, during the 12-month period following the 
imatinib treatment initiation date  
Patients with short-term use of imatinib “short-term 
group”: treated with imatinib continuously between 
6 months to 12 months
(N=406)
Patients with long-term use of imatinib “long-term 




Fig. 1 Sample selection
Table 1 Comparison of patient
characteristics between patients
with short-term versus long-term
imatinib use







Age at index date, mean± SD 58.06±9.43 59.16±9.82 0.113
Male, n (%) 282 (69.5) 240 (59.1) 0.002a
Ethnicity/race, n (%)
Caucasian 304 (74.9) 289 (71.2) 0.236
Hispanic 34 (8.4) 41 (10.1) 0.396
Black 38 (9.4) 50 (12.3) 0.176
Asian 27 (6.7) 22 (5.4) 0.461
Native American 2 (0.5) 4 (1.0) 0.412
Other 1 (0.2) 0 (0.0) -
Comorbid conditions, n (%)
Hypertension 155 (38.2) 152 (37.4) 0.828
Hyperlipidemia 98 (24.1) 97 (23.9) 0.935
Diabetes 59 (14.5) 79 (19.5) 0.062
Anemia 60 (14.8) 73 (18.0) 0.218
Cardiovascular 23 (5.7) 46 (11.3) 0.004 a
Ischemic heart disease 6 (1.5) 17 (4.2) 0.020 a
Renal failure 5 (1.2) 11 (2.7) 0.130
Other 3 (0.7) 8 (2.0) 0.129
Other heart disease 5 (1.2) 2 (0.5) 0.255
Cancer other than GIST 5 (1.2) 2 (0.5) 0.255
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(1) these tests were not a standard of care, and/or there was no
indication to do it (long-term, 35%, short-term, 36%, p00.683)
and (2) patient management course would not change based on
results/physicians were not aware of the impact on therapy
management (long-term, 35 %, short-term, 27 %, p00.106).
Treatment Characteristics
On average, patients in the short-term and long-term groups
were treated with imatinib for approximately 10 and
27 months, respectively (Table 3). Patients were generally






Mitotic rate, n (%)
<5/50 HPF 39 (9.6) 71 (17.5) 0.001a
5/50 HPF 129 (31.8) 128 (31.5) 0.940
6–10/50 HPF 137 (33.7) 123 (30.3) 0.292
>10/50 HPF 69 (17.0) 56 (13.8) 0.206
Unknown 32 (7.9) 28 (6.9) 0.592
Tumor size, n (%) 8.10±6.88 6.89±6.29 <0.001 a
<2 cm 2 (0.5) 12 (3.0) 0.007 a
2–5 cm 113 (27.8) 167 (41.1) <0.001 a
6–10 cm 227 (55.9) 187 (46.1) 0.005 a
>10 cm 64 (15.8) 40 (9.9) 0.012 a
Miettinen risk, mean±SD 0.39±0.32 0.32±0.33 0.004 a
Fletcher risk categories, n (%)
Very low risk 1 (0.2) 4 (1.0) 0.178
Low risk 55 (13.5) 102 (25.1) <0.001 a
Intermediate risk 111 (27.3) 101 (24.9) 0.424
High risk 197 (48.5) 162 (39.9) 0.013 a
Unknown 42 (10.3) 37 (9.1) 0.554
GIST location, n (%)
Stomach 218 (53.7) 188 (46.3) 0.035 a
Small intestine 121 (29.8) 118 (29.1) 0.817
Colon 26 (6.4) 34 (8.4) 0.283
Rectum 5 (1.2) 9 (2.2) 0.281
Pelvis 3 (0.7) 15 (3.7) 0.004 a
Number of patients with no mutation analyses performed, n (%) 199 (49.0) 209 (51.5) 0.483
Reasons why KIT mutation tests were not performed, n (%)
Not a standard of care/no indications to do it 70 (34.8) 75 (35.7) 0.683
Would not have change therapy/management or the physician was not
aware of how the results should have impact GIST management decision
69 (34.7) 57 (27.3) 0.106
Pathology issues (i.e., pathologist elsewhere or patient had surgery elsewhere
and could not get tissue, mishandled by pathology department, or not
enough tissue)
7 (3.5) 8 (3.8) 0.868
Cost/no insurance/ patient decision 9 (4.5) 19 (9.1) 0.068
Already tested (results not available) 5 (2.5) 7 (3.3) 0.617
C-KIT was positive, therefore no further testing 13 (6.5) 5 (2.4) 0.042 a
Not ordered by surgeon 0 (0.0) 8 (3.8) –
Don’t know 1 (0.5) 1 (0.5) 0.972
Testing was not available 27 (13.6) 30 (14.4) 0.819
The five most frequent GIST locations in the short-term group are reported. Other GIST locations included omentum (short-term 2.7 %, long-term
1.2 %), retroperitoneum (short-term 2.5 %, long-term 2.7 %), gastroesophageal junction (short-term 2.2 %, long-term 1.2 %), appendix (short-term
1.5 %, long-term 2.0 %), esophagus (short-term 1.2 %, long-term 0.5 %), pancreas (short-term 0.2 %, long-term 0.2 %), and liver (short-term 0.0 %,
long-term 0.2 %), and differences were not statistically significantly different between the two groups
a Significant at the 5 % level
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initiated on imatinib 400 mg (95 % in both groups, p0
0.631) as recommended in guidelines, and most patients
were still treated with imatinib on the same dose over the
observation period; few patients had an imatinib dose in-
crease (short-term, 0.7 % versus long-term, 1.0 %, p00.716)
or decrease (short-term, 4.7 % versus long-term, 3.0 %, p0
0.187) or switched to sunitinib (short-term, 2.7 % versus
long-term, 0.7 %, p00.037) (results not presented).
Reasons reported by physicians for treating patients with
adjuvant imatinibwere similar across the two groups (Table 2).
The two main reasons reported were: per treatment guidelines
(long-term, 74 %, short-term, 70 %, p00.241) and the risk of
recurrence (long-term, 51 %, short-term, 45 %, p00.106).
Characteristics of Surveyed Physicians and Perception
of Outcomes
Among the 318 surveyed physicians, most were medical
oncologists (47 %) or hematologists/oncologists (51 %),
working in a private practice setting (78 %) of small or
intermediate size (54 %) (i.e., two to nine oncologists)
(results not presented).
Overall, 86 % of the physicians believed that long-term
imatinib treatment reduced the risk of disease recurrence;
these physicians reported that 52 % of their patients received
long-term imatinib therapy whereas 48 % received short-term
therapy. In contrast, among physicians who did not believe in
the benefits of long-term imatinib treatment, a greater propor-
tion of their patients were treated with short-term therapy
(59 % versus 41 %). Although patient’s risk profile was the
main factor considered in a physician’s decisions to prescribe
long-term imatinib adjuvant therapy (78 % of physicians),
drug tolerability (72 %), age (younger) (61 %), safety profile
(39 %), treatment response (28 %), and financial reasons
(27 %) were also other important considerations for treatment
duration related decisions (results not presented).
Clinical Outcomes
Risk of Disease Recurrence
Over the observation period, compared with long-term
patients, significantly more patients in the short-term group
had at least one disease recurrence (5.9 % versus 1.2 %, p<
0.001) (Table 4). Among patients who had a disease recur-
rence, the median time between surgery and the first disease
recurrence was 730 and 717 days for short-term and long-
term patients, respectively (results not presented). After
controlling for confounders, the adjusted risk of recurrence
was 5.30 times (95 % CI, 2.00–14.07, p<0.001) higher in
the short-term group (Table 4).
Mortality Risk
The use of imatinib over a longer time period was also
associated with a reduction in mortality (Table 4). Com-
pared with patients in the long-term group, significantly
more patients in the short-term group died during the obser-
vation period (7.1 % versus 2.0 %, p<0.001) (Table 4).
After controlling for confounding factors, the adjusted mor-
tality rate was 4.02 times (95 % CI, 1.82–8.90, p<0.001)
higher in the short-term group.
Discussion
Tumor resection with clear margins is the mainstay of treat-
ment for localized primary resectable GIST [12]. However,






Duration of imatinib treatment (in months), mean±SD 26.73±10.43 10.36±2.15 <0.001a
Average initial dose of imatinib
Dose <400 mg, n (%) 7 (1.7) 5 (1.2) 0.561
Dose0400 mg, n (%) 387 (95.3) 384 (94.6) 0.631
Dose >400 mg, n (%) 12 (3.0) 17 (4.2) 0.344
Reason for the choice of imatinib as adjuvant therapy, n (%)
Per treatment guidelines 300 (73.9) 285 (70.2) 0.241
Patient was at increased risk of recurrence 207 (51.0) 184 (45.3) 0.106
Evidence of residual microscopic disease 8 (2.0) 17 (4.2) 0.067
Results of KIT mutation tests 57 (14.0) 53 (13.1) 0.682
The physician treats all patients with imatinib 90 (22.2) 98 (24.1) 0.506
Other 5 (1.2) 4 (1.0) 0.737
a Significant at the 5 % level
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studies showed that one out of two patients generally relapse
at some point after curative surgery [9]. This study showed
that, compared with long-term patients, the risk of recurrence
was 5.30 times higher andmortality risk was 4.02 times higher
in patients with short-term adjuvant imatinib use, suggesting
that patients with primary resectable GISTwould benefit from
long-term treatment with adjuvant imatinib. These findings
are consistent with results from a recent multicenter, prospec-
tive, randomized Phase III study which showed superior RFS
(65.6 % versus 47.9 %) and overall survival (92.0 % versus
81.7 %) at 5 years among patients receiving longer adjuvant
imatinib treatment (3 versus 1year) [11, 15, 16]. According to
the 2012 NCCN Guidelines, postoperative use in of imatinib
for at least 36 months should be considered in high-risk
patients [12]. Though benefits of long-term treatment are
clearly illustrated in the published literature as well as in our
study, in practice, the key debate around factors to be consid-
ered by physicians to appropriately select patients for long-
term adjuvant imatinib treatment remains unresolved.
The published literature suggests that all factors including
tumor size, location, mitotic count, and tumor rupture during
surgery should be considered while determining patients’ risk
of recurrence. However, results from our study showed that,
among these, only tumor size and mitotic count seemed to
play an important role in the treatment duration decision. In
addition, although tumor rupture during surgery or a GIST
location outside of the stomach have been associated with
higher risk of recurrence, no significant differences were
observed in our study [17]. Tumor rupture occurred rarely,
which may account for our observation (see Table 2). The
choice between long-term and short-term imatinib therapy
was primarily dependent on the assessment of patients’ pre-
treatment risk of recurrence. Physicians’ perception of the
effectiveness of long-term imatinib treatment in reducing the
risk of recurrence also played an important role; patients who
received long-term imatinib seemed to have a higher pre-
treatment risk profile compared with patients on short-term
imatinib treatment. Although the proportion of patients with a
high-risk profile (based on Fletcher classification) was higher
in the long-term imatinib group, the proportion was also high
in the short-term group (39.9 %), suggesting that a sizeable
proportion of high-risk patients who should be treated for
longer duration were receiving short-term imatinib treatment.
Although there is no consensus on the role of mutational
testing as a prognostic factor, especially in non-metastatic
patients, studies have shown a high association between the
presence of KIT mutations and treatment response to tyro-
sine kinase inhibitors [18]. The role of mutational testing in
determining imatinib treatment duration and dose for ad-
vanced/metastatic disease has been recognized in the litera-
ture. Recent studies have also shown that mutational status
can be considered as a prognostic factor in patients with
localized GIST treated with adjuvant imatinib [18–20].
However, to date, there are no clear recommendations re-
garding the need to perform systematic KIT mutational
testing in non-metastatic primary GIST patients. According
to the NCCN Task Force Report, mutation analysis is not
“routinely recommended” at diagnosis [1]. However, the
NCCN report also indicates that the mutational analysis
may be useful in selecting patients for postoperative therapy
after complete resection of primary GIST, by identifying
patients at higher risk for recurrence [1]. However, in our
study, KIT mutation status was known in only 50 % of
patients in both treatment groups. The two main reasons
indicated by physicians for not performing KIT mutation
tests were that (1) they were not considered standard of care
and that the results would not have changed treatment
decision and (2) the physician was not aware of how the
results should impact treatment decisions. The relatively
high percentage of patients with a high risk profile in the
short-term group and the relatively low percentage of
patients for whom the mutational testing was performed
suggest a lack of consensus about risk assessment methods
and the importance of considering mutational testing in
GIST patients using imatinib adjuvant treatment.
To the best of our knowledge, this is the first study to
compare the risk of recurrence and mortality in GIST
patients treated with short-term versus long-term adjuvant
imatinib therapy in a non-trial setting and to collect infor-
mation about physicians’ perceptions of risk in treatment
decisions. Findings from this study provide information on
the benefits of long-term imatinib use and a more complete
picture of the characteristics of GIST patients treated with
imatinib over a shorter versus longer period of time and
prescribing decision drivers among physicians in a non-trial
setting.
Table 4 Comparison of rates of disease recurrence and mortality between patients with short-term versus long-term imatinib use




P value P value
Long-term patients Short-term patients
Disease recurrence 5 (1.2) 24 (5.9) <0.001a 5.49 (2.09–14.40) <0.001 a 5.30 (2.00–14.07) <0.001 a
Mortality 8 (2.0) 29 (7.1) <0.001 a 4.19 (1.91–9.19) <0.001 a 4.02 (1.82–8.90) <0.001 a
a Significant at the 5 % level
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The present study is subject to common limitations that
are inherent to retrospective studies using patient chart sur-
veys. First, the generalizability of these findings may be
limited if patients treated by physicians who participated
in the survey had systematically different characteristics
from patients treated by physicians who did not. However,
in order to ensure a representative sample, every effort was
made to recruit physicians and to collect information on
randomly selected patients. Second, an inherent limitation
of the patient selection is that patients in the long-term group
had to survive for at least 24 months while patients in the
short-term group survived for a minimum of 6 months. To
minimize this potential bias, short-term patients were select-
ed only if imatinib was discontinued for a reason other than
death. In addition, patients in the long-term group were
excluded only if they had a recurrence during the first
12 months of treatment. Therefore, some patients may have
had a recurrence between 12 and 24 months after imatinib
initiation, that is, before they can benefit from the long-term
imatinib use. Third, the impact of imatinib treatment dura-
tion on the risk of recurrence and mortality might vary
depending on patients’ risk profile. Although we did control
for patients’ pre-treatment risk profile in multivariate regres-
sion analyses, due to the relatively small sample size and
small number of events, results were not stratified by risk
profile. Further research would be warranted to analyze the
impact of imatinib treatment duration on disease recurrence
and mortality for specific risk profile subgroups.
Conclusion
Results from our study showed that, despite the higher risk
profile of long-term imatinib patients, the use of imatinib
over a longer period of time was associated with a reduction
in long-term risk of disease recurrence and mortality. The
patient’s pre-treatment risk profile and physicians’ percep-
tion of the effectiveness of long-term imatinib treatment
were the main factors that drove the decision to treat a
patient with imatinib over a shorter versus a longer period
of time, although a relatively high proportion of patients in
the short-term group had a high-risk profile. The significant
percentage of patients with a high-risk profile in the imatinib
short-term treatment group and the low percentage of
patients for whom mutational testing was performed suggest
that more education is needed to better inform physicians
about risk assessment and the importance of considering
mutational testing in GIST patients using imatinib adjuvant
treatment.
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